Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATX3
- Development stage
- Preclinical
- Lead developer
- Aurobac Therapeutics
- Modality
- Small Molecules
01
Overview
ATX3 is an early-stage drug discovery program being developed by Aurobac Therapeutics, a biopharmaceutical joint venture founded by Boehringer Ingelheim, Evotec, and bioMérieux. The program utilizes a hit discovery collaboration focused on natural products, specifically mining microbial diversity to identify novel chemical scaffolds. ATX3 is being developed for the treatment of infections caused by Gram-negative pathogens, aiming to address the high unmet medical need in antimicrobial resistance. As the program is currently in the discovery and preclinical phase, specific details regarding its precise biological target and chemical structure have not been publicly disclosed.
Beyond the preview
Go deeper on ATX3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATX3.